The COVID-19 pandemic has triggered several changes in the pharmaceutical sector across the world with several companies adopting decentralised clinical trials (DCTs) to minimise disruptions.
GlobalData conducted a survey to identify the biggest challenges of decentralised/ virtual trials.
Biggest Challenges Facing Decentralised Clinical Trials
The survey found that the changes required to procedures, processes, and/or systems while conducting DCTs emerged as the biggest challenge for the industry.
A total of 21% of the respondents expect that the implementation of such changes will be the number one challenge while transitioning to DCTs.
Unclear regulatory acceptance was the second biggest concern with 16% of the respondents highlighting the challenges of tracking the changes in regulatory guidance while conducting decentralised trials.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt was followed by the concerns regarding the ability of the investigators to perform their regulatory duty (11%) and overall quality of the study data (9%).
Around 8% of the respondents highlighted lack of data integration, while another 8% opined additional complexities to be a user of study related systems was the biggest challenge for DCTs.
Change of management, more complexities to be a study site and investigators performing system validation was viewed as the biggest challenge by 6%, 5% and 5% of the respondents, respectively.
Risks of cost increase (4%), safety of patients (4%) and the need for additional study site personnel to conduct a study (2%) also concerned the industry.
The remaining 1% of the respondents highlighted other challenges.
The analysis is based on responses received for the Coronavirus Survey – COVID-19 and Decentralised Clinical Trials conducted by GlobalData between 04 June and 22 June 2020.
